Global Short Bowel Syndrome Market Insights, Share, Size, and Report 2032

Global Short Bowel Syndrome Market Insights, Share, Size, and Report 2032

DelveInsight’s Short bowel syndrome Market Insights report provides a thorough understanding of current treatment practices, emerging Short bowel syndrome market share of the individual therapies, current and forecasted Short bowel syndrome market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).


Short Bowel Syndrome Overview

Short bowel syndrome (SBS) is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. SBS is generally broken down into individuals in whom the disorder is acquired during life and newborns in which the disorder is present at birth (congenital). Acquired short bowel syndrome is more common than the congenital form of the disorder.


Some of the key highlights of the short bowel syndrome market report

  • Studies conducted by Dabney et al. and Amiot et al. suggest that women are more likely to suffer from SBS as compared to men.
  • Acquired SBS cases are more common, whereas congenital SBS is a relatively rare condition.
  • In Europe the prevalence of SBS tends to be lower in regions lacking major intestinal rehabilitation centers and strong home PN/IV programs, likely due to underreporting.
  • Short bowel syndrome companies are included like Takeda, Zealand Pharma, VectivBio AG, 9 Meters Biopharma, and many others.
  • Short bowel syndrome drugs are included like Gattex (teduglutide), Glepaglutide, Apraglutide, and many others.



Short bowel syndrome Symptoms

The specific symptoms and severity of SBS vary from one person to another. Diarrhea is common, often severe and can cause dehydration, which can even be life-threatening. SBS can lead to malnutrition, unintended weight loss, and additional symptoms may be due to the loss of essential vitamins and minerals.


Short bowel syndrome Causes

In some cases, newborns can be born with a shortened bowel that is present at birth (congenital short bowel syndrome). The exact cause of a short bowel in these cases is not fully understood and several different theories have been proposed. More research is necessary to determine what factors ultimately lead to congenital short bowel syndrome.


Short bowel syndrome Treatment

The treatment of SBS is directed toward the specific symptoms that are apparent in each individual. It includes nutritional support, medications, surgery, and intestinal transplant. The specific therapeutic procedures and interventions for individuals with a short bowel syndrome might vary, depending upon numerous factors, including the specific symptoms, the site and extent of the affected portion of the small intestine, whether the colon is involved, an individual’s age and overall health, tolerance of certain medications or procedures, personal preference, and other factors.


Find a snapshot of the Short bowel syndrome Market Share


Short Bowel Syndrome Market Report Scope

  • The report covers the descriptive overview of Short Bowel Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Short Bowel Syndrome epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Short Bowel Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Short Bowel Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Short Bowel Syndrome market


Short Bowel Syndrome Companies

  • Takeda
  • Zealand Pharma
  • VectivBio AG
  • 9 Meters Biopharma
  • And many others


Short Bowel Syndrome Drugs

  • Gattex (teduglutide)
  • Glepaglutide
  • Apraglutide
  • And many others


Get detailed information about drugs @ Short Bowel Syndrome Marke Size


Table of content

  1. Key Insights
  2. Executive Summary
  3. Competitive Intelligence Analysis
  4. Market Overview at a Glance
  5. Disease Background and Overview
  6. Patient Journey
  7. Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Short Bowel Syndrome Treatment
  11. Marketed Products
  12. Emerging Therapies
  13. Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview
  17. KOL Views
  18. Market Drivers
  19. Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight


About Us

DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.


Contact Us


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States